drugset / Trial / NCT05984251

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

NCT05984251

Phase 1 Completed 48 enrolled Amgen
RandomizedSequentialDouble-blindBasic science

Summary

The primary objective of this study will be to evaluate the safety and tolerability of single and multiple oral doses of CCX168, over a range of dose levels, in healthy male and female participants.

Timeline

Start
2009-12-21
Primary completion
2010-09-19
Completion
2011-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Avacopan Small molecule 1 mg Oral
Subject Avacopan Small molecule 3 mg Oral
Subject Avacopan Small molecule 10 mg Oral
Subject Avacopan Small molecule 30 mg Oral
Subject Avacopan Small molecule 100 mg Oral